Tag Archives: Pharmaceuticals

BlissCo Cannabis

Supreme Pharmaceuticals Closes $40.25 Million Bought Deal Private Placement of Convertible Debenture Units

Supreme Pharmaceuticals Closes $40.25 Million Bought Deal Private Placement of Convertible Debenture Units

TORONTO, Ontario, Nov. 14, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (TSXV:FIRE) is pleased to announce the closing of its previously announced bought deal private placement of 40,250 convertible debenture units (the “Convertible Debenture Units”), including the exercise of the Underwriters’ over-allotment option (the “Offering”), with a syndicate of underwriters, led by Canaccord Genuity Corp., including Beacon Securities Limited, Cormark Securities Inc., Eight Capital, GMP Securities L.P., and PI Financial Corp., for gross proceeds of approximately $40.25 million.

BlissCo Cannabis

Supreme Receives Approval for Increased Capacity at 7ACRES Hybrid Facility

TORONTO, Ontario, Oct. 23, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (TSXV: FIRE) announced today that 7ACRES has obtained the Health Canada approvals necessary to commence cultivation at the recently completed 30,000 sq. ft. flowering rooms at the Company’s Hybrid facility.

ASTM Stakeholders cannabis workshop

ASTM – Cannabis Standards Group Approved, Launches June 11 in Canada

W. CONSHOHOCKEN,Penn., April 25, 2017 /Weed Wire/ — ASTM International, one of the world’s leading standards organizations, announced today that its board of directors has approved the formation of a committee on cannabis (D37). The organization also announced that the committee will hold its first official meeting June 11-12 in Toronto.

Aurora Cannabis operational update

Aurora Completes Acquisition of Peloton Pharmaceuticals Inc.

VANCOUVER, British Columbia, April 4, 2017 /Weed Wire/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSXV: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) is pleased to announce that, further to its press release of March 6, 2017, the Company has completed the acquisition of Peloton Pharmaceuticals Inc. (“Peloton”), a Montreal-area late-stage ACMPR-applicant.

SeeThruEquity RSHO Raúl Elizalde

Study Results: Medical Marijuana, Inc. Subsidiary HempMeds Mexico Announces Release of Study Using Its Real Scientific Hemp Oil-X to Treat Epileptic Children

SAN DIEGO, Calif., March 14, 2017 /Weed Wire/ — Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Mexico is holding a press conference in Mexico City, Mexico, today to reveal the positive results of a recent study conducted by renowned Mexican physician Dr. Saul Garza Morales on the effects of the Company’s Real Scientific Hemp Oil-X™ (RSHO-X™) product in treating children with severe epilepsy.

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.


InMed Pharmaceuticals, Inc. Appoints Senior Vice President, Clinical and Regulatory Affairs

VANCOUVER, British Columbia, Oct. 31, 2016 /Weed Wire/ — InMed Pharmaceuticals, Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), today announced the appointment of Alexandra D.J. Mancini, M.Sc., as Senior Vice President, Clinical and Regulatory Affairs.

Supreme Pharma

Supreme Closes Second Tranche of Private Placement for Aggregate Proceeds of $4.34m and Secures Additional Long Term Supply Agreement

TORONTO, Ontario, July 15, 2016 /Weed Wire/ — Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (CSE:SL)(OTC PINK:SPRWF) is pleased to announce it has closed the second tranche of its previously announced non-brokered private placement (the “Financing”) for proceeds of $723,250 and aggregate proceeds from both tranches of $4,339,130.


InMed Announces Appointment of Eric A. Adams as CEO, President and Director

VANCOUVER, British Columbia, June 16, 2016 /Weed Wire/ — InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE:IN)(OTCQB:IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies, is pleased to announce today the appointment of Mr. Eric A. Adams as CEO, President and as a member of the Board of Directors.


Zynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Highlights

DEVON, Pa., May 12, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the quarter ended March 31, 2016, and provided an overview of recent operational highlights.


New Study Confirms Patients Substitute Cannabis for Rx Drugs

Plenty of anecdotal evidence suggests people suffering from pain, nausea, anxiety or other forms of emotional distress often swap their prescription drugs for marijuana. A new study completed by the Centre for Addictions Research of British Columbia adds yet more scientific rigor to the casual observations.


Food as Pharma?

On the surface, the recent High Times Cannabis Cup in Seattle appeared to be one big counter culture smoke fest for “Free the Weed!” enthusiasts. With reggae music pumping and Twitter ablaze with photos of cannabis dabbing Millennials blowing psychotropic smoke rings, there were clusters of grizzled gray beards and former hippies now eligible for AARP discounts.


Just Say No to Small Marijuana Stocks

Given the title of yesterday’s Market Musings piece and the subject of today’s, you, dear reader, could be forgiven for thinking that I have some kind of a drug problem. I can assure you that I don’t. I just have a problem with some drug stocks, both the non-conventional and more traditional.